Loading...

We've got a brand new version of Simply Wall St! Try it out

XPhyto Therapeutics

CNSX:XPHY
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XPHY
CNSX
CA$61M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

XPhyto Therapeutics Corp., through its subsidiaries, operates in the medicinal cannabis industry in Canada and Germany. The last earnings update was 74 days ago. More info.


Add to Portfolio Compare Print
XPHY Share Price and Events
7 Day Returns
0%
CNSX:XPHY
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:XPHY
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
XPHY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
XPhyto Therapeutics (XPHY) 0% 0% - - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on XPHY.
  • No trading data on XPHY.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is XPhyto Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for XPhyto Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is CA$1.3.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for XPhyto Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are XPhyto Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:XPHY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.06
CNSX:XPHY Share Price ** CNSX (2019-09-20) in CAD CA$1.3
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of XPhyto Therapeutics.

CNSX:XPHY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:XPHY Share Price ÷ EPS (both in CAD)

= 1.3 ÷ -0.06

-20.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XPhyto Therapeutics is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • XPhyto Therapeutics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does XPhyto Therapeutics's expected growth come at a high price?
Raw Data
CNSX:XPHY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for XPhyto Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on XPhyto Therapeutics's assets?
Raw Data
CNSX:XPHY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.16
CNSX:XPHY Share Price * CNSX (2019-09-20) in CAD CA$1.3
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:XPHY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:XPHY Share Price ÷ Book Value per Share (both in CAD)

= 1.3 ÷ 0.16

8.33x

* Primary Listing of XPhyto Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XPhyto Therapeutics is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess XPhyto Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. XPhyto Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is XPhyto Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XPhyto Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is XPhyto Therapeutics expected to grow at an attractive rate?
  • Unable to compare XPhyto Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare XPhyto Therapeutics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare XPhyto Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:XPHY Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:XPHY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:XPHY Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 -2 -2
2019-03-31 -1 -2
2018-12-31 -1 -1
2017-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if XPhyto Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if XPhyto Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:XPHY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from XPhyto Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:XPHY Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.06
2019-03-31 -0.06
2018-12-31 -0.04
2017-12-31 -0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if XPhyto Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine XPhyto Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. XPhyto Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. XPhyto Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess XPhyto Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
XPhyto Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has XPhyto Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare XPhyto Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • XPhyto Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare XPhyto Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare XPhyto Therapeutics's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
XPhyto Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from XPhyto Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:XPHY Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -2.33 1.60 0.07
2019-03-31 -1.65 1.17 0.06
2018-12-31 -0.86 0.76
2017-12-31 -0.05 0.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if XPhyto Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if XPhyto Therapeutics has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if XPhyto Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess XPhyto Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
XPhyto Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is XPhyto Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up XPhyto Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • XPhyto Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • XPhyto Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of XPhyto Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • XPhyto Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from XPhyto Therapeutics Company Filings, last reported 2 months ago.

CNSX:XPHY Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 7.35 0.00 2.14
2019-03-31 8.03 0.00 2.71
2018-12-31 7.76 0.00 2.37
2017-12-31 0.02 0.00
  • XPhyto Therapeutics has no debt.
  • XPhyto Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • XPhyto Therapeutics has less than a year of cash runway based on current free cash flow.
  • XPhyto Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 114.8% each year.
X
Financial health checks
We assess XPhyto Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. XPhyto Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is XPhyto Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from XPhyto Therapeutics dividends.
If you bought CA$2,000 of XPhyto Therapeutics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate XPhyto Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate XPhyto Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:XPHY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as XPhyto Therapeutics has not reported any payouts.
  • Unable to verify if XPhyto Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of XPhyto Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as XPhyto Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess XPhyto Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can XPhyto Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. XPhyto Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of XPhyto Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hugh Rogers
AGE 39
CEO Bio

Mr. Hugh A.D Rogers, B.Sc., LL.B has been the Chief Executive Officer at Coronado Resources Ltd. since March 6, 2015. Mr. Rogers serves as the Chairman of the Board at 3D Signatures Inc. Mr. Rogers served the Interim Chairman of 3D Signatures Inc since September 17, 2018. He serves as the Chief Executive Officer, President and Director of Seashore Resource Partners Corp. He served as Chief Executive Officer, Chief Financial Officer and President at Angus Ventures Inc until July 25, 2017. He served as Vice President of Corporate Finance at 3D Signatures Inc., since April 2015. Since November 2011, Mr. Rogers has been self employed as a corporate finance consultant. He is a Co-Owner of SXR Capital Corp. He is an entrepreneur and lawyer with broad private and public company experience in corporate finance, business strategy, regulatory compliance and Investor Relations. He has corporate finance and restructuring experience through his work with various TSX-V listed issuers. From December 2012 to June 2013, he was responsible for business development of Huldra Silver Inc. From November 2011 to November 2012, Mr. Rogers served as a self-employed corporate development consultant located in Vancouver, British Columbia. From April 2011 to October 2011, he served as Corporate Counsel for Zimtu Capital Corp., a corporation that invests in mining and resources. From May 2010 to March 2011, he was self-employed as an attorney specializing in litigation. From May 2009 to April 2010, he was an Articled Student for Legal Services Society of British Columbia. He has been Director at Kootenay Zinc Corp., since September 2016. He has been a Director of Coronado Resources Ltd. since March 6, 2015. He served as Director of RepliCel Life Sciences Inc. since February 3, 2017 to December 14, 2018. He was a Director of Vizsla Resources Corp. from September 26, 2017 to January 2019. He served as Director at Angus Ventures Inc. He served as Independent Director of McorpCX, Inc. since November 20, 2015 until February 1, 2017. He is an active Member of The Law Society of British Columbia Mr. Rogers is an attorney licensed to practice law in British Columbia. He is a Member in good standing of the Law Society of British Columbia. Mr. Rogers served as Outside Director at Clear Blue Technologies International Inc. until June 17, 2019. Mr. Rogers serves as a President and Chief Executive Officer and Director at Xphyto Therapeutics Corp. He holds a B.Sc. degree from the University of British Columbia and holds a Legum Baccalaureus (LLB) degree from University of New Brunswick. His corporate finance, restructuring and regulatory experience has been primarily focused on start-ups and small cap companies in the resource and biotechnology industries.

CEO Compensation
  • Insufficient data for Hugh to compare compensation growth.
  • Insufficient data for Hugh to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Hugh Rogers

TITLE
President
AGE
39

Chris Ross

TITLE
Chief Financial Officer

Robert Barth

TITLE
VP European Corporate Development
Board of Directors

Hugh Rogers

TITLE
President
AGE
39

Raimar Löbenberg

TITLE
Director

Wolfgang Probst

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess XPhyto Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. XPhyto Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Insiders Own Lots Of Shares In XPhyto Therapeutics Corp. (CNSX:XPHY)?

Taking a look at our data on the ownership groups (below), it's seems that institutions don't own shares in the company. … See our latest analysis for XPhyto Therapeutics CNSX:XPHY Ownership Summary, August 7th 2019 What Does The Lack Of Institutional Ownership Tell Us About XPhyto Therapeutics? … General Public Ownership The general public, who are mostly retail investors, collectively hold 85% of XPhyto Therapeutics shares.

Simply Wall St -

Company Info

Description

XPhyto Therapeutics Corp., through its subsidiaries, operates in the medicinal cannabis industry in Canada and Germany. It is involved in the production, extraction, isolation, formulation, delivery, marketing, and sale of medicinal cannabis. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Details
Name: XPhyto Therapeutics Corp.
XPHY
Exchange: CNSX
Founded: 2017
CA$61,240,016
47,107,705
Website: http://www.xphyto.com
Address: XPhyto Therapeutics Corp.
701 West Georgia Street,
Suite 1500,
Vancouver,
British Columbia, V7Y 1C6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX XPHY Common Shares Canadian National Stock Exchange CA CAD 06. Aug 2019
DB 4XT Common Shares Deutsche Boerse AG DE EUR 06. Aug 2019
Number of employees
Current staff
Staff numbers
5
XPhyto Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:40
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/10
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.